BeOne Medicines (ONC) Cash from Financing Activities (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Cash from Financing Activities data on file, last reported at $68.6 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 303.19% year-over-year to $68.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 44428.88% YoY) and the FY2025 annual result came in at $1.1 billion, up 447.66% from the prior year.
• Cash from Financing Activities eased to $68.6 million in Q1 2026 per ONC's latest filing, from $96.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $961.3 million in Q3 2025 and bottomed at -$110.4 million in Q4 2022.
• The 5-year median for Cash from Financing Activities is $23.0 million (2024), against an average of $101.1 million.
• The widest annual swing landed in 2023, when Cash from Financing Activities sank 163.86%; it then soared 7491.79% in 2025.
• Tracing ONC's Cash from Financing Activities over 5 years: stood at -$110.4 million in 2022, then soared by 414.45% to $347.0 million in 2023, then plunged by 101.3% to -$4.5 million in 2024, then jumped by 2243.07% to $96.9 million in 2025, then retreated by 29.19% to $68.6 million in 2026.
• Per Business Quant, the three latest ONC Cash from Financing Activities figures stand at $68.6 million (Q1 2026), $96.9 million (Q4 2025), and $961.3 million (Q3 2025).

Peer Comparison